Document Type

Article

Publication Date

9-1-2015

Abstract

© 2015, Springer International Publishing AG. Herpes simplex virus type 1 (HSV-1) and its closely related herpes simplex virus type 2 (HSV-2) cause important clinical manifestations in humans including acute ocular disease and genital infections. These viruses establish latency in the trigeminal ganglionic and dorsal root neurons, respectively. Both viruses are widespread among humans and can frequently reactivate from latency causing disease. Currently, there are no vaccines available against herpes simplex viral infections. However, a number of promising vaccine approaches are being explored in preclinical investigations with few progressing to early-phase clinical trials. Consensus research findings suggest that robust humoral and cellular immune responses may partially control the frequency of reactivation episodes and reduce clinical symptoms. Live-attenuated viral vaccines have long been considered as a viable option for generating robust and protective immune responses against viral pathogens. Varicella zoster virus (VZV) belongs to the same alphaherpesvirus subfamily with herpes simplex viruses. A live-attenuated VZV vaccine has been extensively used in a prophylactic and therapeutic approach to combat primary and recurrent VZV infection, indicating that a similar vaccine approach may be feasible for HSVs. In this review, we summarize preclinical approaches to HSV vaccine development and current efforts to test certain vaccine approaches in human clinical trials. Also, we discuss the potential advantages of using a safe, live-attenuated HSV-1 vaccine strain to protect against both HSV-1 and HSV-2 infections.

Publication Source (Journal or Book title)

Current Clinical Microbiology Reports

First Page

125

Last Page

136

Download
COinS